SEC Form 4													
FO	RM 4	UNITE	D STATES		ES AND E	SION							
					.g.c.i, 2.01 200				OMB APPRO	DVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See		to STA					ERSH	Esti	mated average burg	3235-0287 den 0.5			
Instruction 1(b).			Section 30(h) of the		ties Exchange Act of 1934 Impany Act of 1940		OMB APPROVA OMB Number: 3238 Estimated average burden hours per response: elationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner Officer (give title below) Other (spect below) dividual or Joint/Group Filing (Check Applic Form filed by One Reporting Person Form filed by More than One Reporting Person ract, instruction or written plan that is intended to n 10. y Owned					
1. Name and Address of Reporting Person* Kronenfeld Mark A.				ssuer Name and Tic cira BioSciene			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(First)	(Middle)		oate of Earliest Trans 08/2023	saction (Month	/Day/Year)		Officer (give title	e Other	(specify			
C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890				Amendment, Date	of Original Filed	d (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
							Form filed by More than One Reporting						
(Street)								. 0.0011					
TAMPA	FL	33609	Ri	ule 10b5-1(c)	Transac	tion Indication							
(City) (State) (Zip)				X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									
		Table I - No	on-Derivative	Securities Ac	quired, Dis	posed of, or Benef	icially	Owned					
1 Title of Securi	by (Instr 3)		2 Transaction	24 Deemed	3	4 Securities Acquired (A)	or	5 Amount of	6 Ownershin	7 Nature			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	06/08/2023		M ⁽¹⁾		15,000	Α	\$29.9	32,897	D	
Common Stock	06/08/2023		S ⁽¹⁾		15,000	D	\$37.04 ⁽²⁾	17,897	D	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

															-
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$29.9	06/08/2023		M ⁽¹⁾			15,000	(3)	06/11/2023	Common Stock	15,000	\$0.00	0	D	

Explanation of Responses:

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$36.72 to \$37.43, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The option shares vested in 24 equal successive monthly installments over the 24-month period following the date of grant, subject to the reporting person's continued service as a director.

Remarks:

/s/ Kristen Williams, Attorney-06/12/2023

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.